| Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MCCOURT Thomas A | Chief Executive Officer | Dec 22 | Sale | 11.41 | 46,327 | 528,591 | 574,454 | Dec 23 04:18 PM | | Rickard Jason | SVP, Chief Operating Officer | Dec 16 | Sale | 11.28 | 27,000 | 304,560 | 319,901 | Dec 20 04:08 PM | | McHugh Julie | Director | Dec 14 | Sale | 11.02 | 10,000 | 110,200 | 138,373 | Dec 16 04:06 PM | | MCCOURT Thomas A | Chief Executive Officer | Nov 23 | Sale | 11.58 | 52,644 | 609,618 | 618,545 | Nov 24 04:09 PM | | Shetzline Michael | CMO,SVP,Head-Res&Drug | Nov 23 | Sale | 11.58 | 13,776 | 159,526 | 183,661 | Nov 24 04:08 PM | | Rickard Jason | SVP, Chief Operating Officer | Nov 23 | Sale | 11.58 | 17,193 | 199,095 | 344,665 | Nov 24 04:09 PM | | Silver Ronald | Principal Accounting Officer | Nov 23 | Sale | 11.58 | 1,462 | 16,930 | 61,213 | Nov 24 04:07 PM | | Silver Ronald | Principal Accounting Officer | Aug 16 | Sale | 13.48 | 567 | 7,643 | 62,675 | Aug 18 04:06 PM | | Rickard Jason | SVP, Chief Operating Officer | Aug 16 | Sale | 13.48 | 680 | 9,166 | 361,858 | Aug 18 04:03 PM | | Currie Mark G | Director | Jun 14 | Sale | 11.59 | 23,571 | 273,188 | 570,187 | Jun 16 04:10 PM | | Shetzline Michael | CMO, SVP & Head of Drug Devt. | May 24 | Sale | 12.25 | 2,077 | 25,443 | 197,437 | May 26 04:05 PM | | Rickard Jason | SVP, Chief Operating Officer | May 24 | Sale | 12.25 | 516 | 6,321 | 362,538 | May 26 04:03 PM | | MCCOURT Thomas A | President and Interim CEO | May 24 | Sale | 12.25 | 1,716 | 21,021 | 566,499 | May 26 04:01 PM | | DENNER ALEXANDER J | Director | Mar 10 | Buy | 10.54 | 75,000 | 790,500 | 16,390,000 | Mar 10 07:06 PM | | DENNER ALEXANDER J | Director | Mar 08 | Buy | 10.30 | 150,000 | 1,545,000 | 16,315,000 | Mar 10 07:06 PM | | DENNER ALEXANDER J | Director | Mar 05 | Buy | 10.01 | 175,000 | 1,751,750 | 16,165,000 | Mar 05 07:19 PM | | DENNER ALEXANDER J | Director | Mar 04 | Buy | 10.00 | 250,000 | 2,500,000 | 15,990,000 | Mar 05 07:19 PM | | DENNER ALEXANDER J | Director | Mar 03 | Buy | 10.02 | 350,000 | 3,507,000 | 15,740,000 | Mar 05 07:19 PM | | DENNER ALEXANDER J | Director | Mar 02 | Buy | 9.56 | 500,000 | 4,780,000 | 15,390,000 | Mar 02 08:18 PM | | DENNER ALEXANDER J | Director | Mar 01 | Buy | 9.60 | 344,900 | 3,311,040 | 14,890,000 | Mar 02 08:18 PM | | DENNER ALEXANDER J | Director | Feb 26 | Buy | 9.20 | 505,100 | 4,646,920 | 14,545,100 | Mar 02 08:18 PM | | Owens Edward P | Director | Feb 26 | Buy | 8.90 | 3,000 | 26,700 | 218,954 | Mar 02 04:41 PM | | Shetzline Michael | CMO, SVP & Head of Drug Devt. | Feb 26 | Sale | 9.11 | 4,439 | 40,439 | 160,859 | Mar 02 04:44 PM | | Rickard Jason | SVP, Chief Operating Officer | Feb 26 | Sale | 9.11 | 13,651 | 124,361 | 306,682 | Mar 02 04:43 PM | | MCCOURT Thomas A | President | Feb 26 | Sale | 9.11 | 14,685 | 133,780 | 471,577 | Mar 02 04:40 PM | | Mallon Mark | Chief Executive Officer | Feb 26 | Sale | 9.11 | 30,675 | 279,449 | 470,605 | Mar 02 04:37 PM | | Kilroy Conor | SVP, GC & Secretary | Feb 26 | Sale | 9.11 | 6,989 | 63,670 | 122,336 | Mar 02 04:36 PM | | Consylman Gina | SVP, CFO & Treasurer | Feb 26 | Sale | 9.11 | 18,406 | 167,679 | 336,244 | Mar 02 04:34 PM | | Owens Edward P | Director | Feb 25 | Buy | 9.11 | 5,000 | 45,550 | 215,954 | Feb 26 05:15 PM | | Owens Edward P | Director | Feb 24 | Buy | 9.26 | 7,000 | 64,820 | 210,954 | Feb 26 05:15 PM |
|
